INS and Alzheimer disease: Finally, T3D-959 clinical trials (phases 1 and 2) confirmed its safety and the remediation of neuroinflammatory and neurodegeneration biomarkers, and it seems as if treating AD as a neurometabolic disorder, resulting from hyperglycemia and insulin signaling pathway disturbances, would uncover attractive new approaches in the treatment of T3D.